股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美中嘉和醫學技術發展集團股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 313,874,624 | RMB | | 1 | RMB | | 313,874,624 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 313,874,624 | RMB | | 1 | RMB | | 313,874,624 | | 2. 股份分 ...

Core Viewpoint - The appointment of Jiang Wei as the new president of Meizhong Jiahe Medical Technology Development Group is seen as a significant signal of the company's transition from traditional medical services to an intelligent tumor diagnosis and treatment ecosystem [1][2]. Group 1: Leadership Transition - Jiang Wei, with a strong background in finance and technology, takes over from Fu Xiao, who retired due to age and organizational adjustments [1]. - Jiang Wei has nearly 20 years of experience in investment banking and capital operations, having previously worked at Ernst & Young and China International Capital Corporation (CICC) before joining Meizhong Jiahe in 2020 [1][2]. Group 2: Strategic Focus - The company aims to integrate its diagnostic capabilities and data resources with AI technology, marking a shift where AI becomes a core driver of the group's strategy [2][3]. - Jiang Wei's leadership is expected to enhance diagnostic efficiency and explore the commercial potential of data assets derived from clinical data [3]. Group 3: Industry Context - The healthcare industry is evolving from a focus on expanding physical infrastructure to improving efficiency and algorithms, indicating a competitive shift [4]. - The appointment of a leader with both capital and technical expertise is anticipated to amplify the company's long-standing capabilities in tumor diagnosis through AI and international expansion strategies [4].

Core Viewpoint - The company announced a leadership change, with Fu Jiao stepping down as president and becoming an advisor, while Jiang Wei will take over as the new president starting January 12, 2026 [1] Group 1 - Fu Jiao will transition to the role of advisor and continue as an executive director after stepping down as president [1] - Jiang Wei, aged 45, has been appointed as the new president and has been with the company since 2020, previously working at Ernst & Young and China International Capital Corporation [1]

Core Viewpoint - The appointment of Jiang Wei as the new CEO of Meizhong Jiahe signals a strategic shift from traditional medical services to an intelligent tumor diagnosis and treatment ecosystem, emphasizing the integration of AI technology into core operations [1][3]. Group 1: Leadership Transition - Jiang Wei, with a strong background in finance and technology, takes over as CEO, indicating a focus on leveraging AI in the healthcare sector [2]. - His previous experience in leading the AI business unit positions him well to drive the company's transformation [2]. Group 2: Strategic Focus on AI - The company aims to integrate AI deeply into its core tumor treatment operations, marking a shift where AI becomes a central driver of strategy rather than a supplementary tool [3]. - The focus will be on enhancing diagnostic capabilities and optimizing clinical pathways through AI [4]. Group 3: Data Asset Utilization - Meizhong Jiahe plans to convert its extensive clinical data into standardized data assets for training more precise AI models, potentially exploring commercial opportunities for data [5]. - The company possesses a unique offline tumor hospital network and vast imaging diagnostic data, which can be leveraged for AI advancements [5]. Group 4: International Expansion - The company is looking to actively expand its overseas business, with standardized medical AI products and high-end tumor treatment services being more conducive to international growth [6]. - Jiang Wei's investment banking background provides a strategic advantage in facilitating technology exports and international capital collaborations [6]. Group 5: Industry Evolution - The healthcare industry is shifting from a focus on acquiring resources to enhancing efficiency and algorithmic capabilities [7]. - Jiang Wei's leadership is expected to amplify the company's long-standing tumor treatment capabilities through AI and international strategies, presenting a new narrative in the capital market [8].

Group 1 - The core announcement is about the leadership change at Meizhong Jiahe (02453.HK), where Fu Xiao will step down as the Group President effective January 12, 2026 [1] - Fu Xiao will transition to a consultant role while continuing to serve as an executive director of the group [1] - Jiang Wei has been appointed as the new President of the group, effective from the same date [1]

Group 1 - The company announced a leadership change, with Ms. Fu Xiao resigning as the Group President effective January 12, 2026 [1] - Ms. Fu will continue to serve as a company advisor and remain an executive director [1] - Mr. Jiang Wei has been appointed as the new President, effective January 12, 2026 [1]

Group 1 - The company announced a leadership change, with Ms. Fu Xiao resigning from her position as Group President effective January 12, 2026 [1] - Ms. Fu will continue to serve as a company advisor and remain an executive director [1] - Mr. Jiang Wei has been appointed as the new President, effective January 12, 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 總裁變更 美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公司，統稱「本 集團」）董事（「董事」）會（「董事會」）宣佈，根據本集團內職務調整，付驍女士退 任本集團總裁職務，自二零二六年一月十二日起生效。付驍女士（「付女士」）將成 為本公司顧問，並繼續擔任本集團執行董事職務。 付女士已確認，彼與董事會並無任何分歧，且退任屬於正常繼任計劃，亦無其他 有關其退任之事宜須提請本公司股東（「股東」）和香港聯合交易所有限公司（「聯交 所」）垂注。 公司謹此機會對付女士在擔任總裁期間為本公司作出的寶貴貢獻致以衷心感謝。 委任總裁 董事會欣然宣佈，姜偉先生（「姜先生」）已獲委任為總裁，自二零二六年一月十二 日起生效。 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 1 姜先生於二零 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美中嘉和醫學技術發展集團股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 313,874,624 | RMB | | 1 RMB | | 313,874,624 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 313,874,624 | RMB | | 1 RMB | | 313,874,624 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Core Insights - The announcement from Meizhong Jiahe marks a significant milestone for its proton therapy center in Guangzhou, indicating a successful transition from technology introduction to capability realization in the medical sector [2][5] - The healthcare industry in China is undergoing a structural adjustment, shifting from a "scale dividend" model to one focused on "capability premium," emphasizing the importance of specialized assets with high technical barriers [2] Group 1: Company Performance - Meizhong Jiahe has demonstrated its strength as an industry "standard setter," participating in the formulation of six national clinical guidelines and establishing a strong academic foundation in proton therapy [3] - The company has achieved a comprehensive breakthrough in clinical breadth, depth, and operational efficiency, completing a closed loop from "heavy asset investment" to "high-quality output" [3][4] - The proton therapy center has shown significant growth in patient intake, indicating a strong brand influence and operational efficiency, with all four treatment rooms operating at full capacity [4] Group 2: Industry Context - The recent "2025 China Social Medical New Ecology Conference" highlighted the need for sustainable clinical output from high-cost medical equipment, which is a critical measure of the level of social medical services [2] - The center's service range extends across 31 provinces and over 20 countries, showcasing its international reach in high-end medical services, particularly in pediatric proton therapy [4] - The completion of China's first proton treatment for ocular malignant melanoma in July 2025 fills a domestic gap and reinforces the center's position in high-difficulty tumor treatments [4]